Emmaus Life Sciences Inc (OTCQX: EMMA), a commercial-stage biopharmaceutical company involved in the treatment of sickle cell disease, announced on Tuesday its financial results for the nine months ended 30 September 2023.
Net revenue for the period increased to USD22.5m compared to USD12.5m in January-September 2022.
Total operating expenses rose to USD19.2m from USD15.7m in the year-ago period.
Income from operations for the nine months to 30 September 2023 increased to USD2.2m, compared to a loss from operations of USD5.2m a year earlier. Emmaus recorded a net loss of USD4.9m, or USD0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares, an improvement from the net loss of USD10.8m or USD0.22 per share, based on approximately 49.4 million weighted average basic and diluted common shares, for the nine months to 30 September 2022.
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties
ValiRx subsidiary Inaphaea extends drug repurposing deal with Dominion Biotech
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
ANI Pharmaceuticals announces buyout of royalty obligation for ILUVIEN and YUTIQ
Sirum collaborates with Governor Wes Moore to expand medication access across Maryland